Page 197 - 80 guidelines for the treatment of malaria_opt
P. 197

ANNEX 9. Treatment of Plasmodium vivax, P. ovale and P. malariae infections



           30.  Tan-ariya P et al. Clinical response and susceptibility in vitro of Plasmodium vivax to the
                standard regimen of chloroquine in Thailand. Transactions of the Royal Society of Tropical
                Medicine and Hygiene, 1995, 89:426–429.
           31.   Baird JK et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia.
                Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90:409–411.
           32.  Baird JK et al. Chloroquine sensitive Plasmodium falciparum and P. vivax in central
                Java, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996,
                90:412–413.
           33.   Baird JK et al. Survey of resistance to chloroquine of falciparum and vivax malaria in
                Palawan, the Philippines. Transactions of the Royal Society of Tropical Medicine and Hygiene,
                1996, 90:413–414.
           34.  Fryauff DJ et al. Survey of resistance in vivo to chloroquine of Plasmodium falciparum and
                P. vivax in North Sulawesi, Indonesia. Transactions of the Royal Society of Tropical Medicine
                and Hygiene, 1998, 92:82–83.
           35.   Looareesuwan S et al. Chloroquine sensitivity of Plasmodium vivax in Thailand. Annals
                of Tropical Medicine and Parasitology, 1999, 93:225–230.
           36.  Fryauff DJ et al. In vivo responses to antimalarials by Plasmodium falciparum and P. vivax
                from isolated Gag Island of northwest Irian Jaya, Indonesia. American Journal of Tropical
                Medicine and Hygiene, 1999, 60:542–546.
           37.   Taylor WRJ et al. Assessing drug sensitivity of Plasmodium vivax to halofantrine or
                chloroquine in southern, central Vietnam using an extended 28-day in vivo test and
                polymerase chain reaction genotyping. American Journal of Tropical Medicine and Hygiene,
                2000, 62:693–697.
           38.  Pukrittayakamee S et al. Therapeutic responses to different antimalarial drugs in vivax
                malaria. Antimicrobial Agents and Chemotherapy, 2000, 44:1680–1685.
           39.   McGready R et al. The effects of quinine and chloroquine antimalarial treatments in the
                first trimester of pregnancy. Transactions of the Royal Society of Tropical Medicine and
                Hygiene, 2002, 96:180–184.
           40.  Yadav RS, Ghosh SK. Radical curative efficacy of five-day regimen of primaquine for
                treatment of Plasmodium vivax malaria in India. Journal of Parasitology, 2002, 88:1042–
                1044.
           41.   Nandy A et al. Monitoring the chloroquine sensitivity of Plasmodium vivax from Calcuta
                and Orissa, India. Annals of Tropical Medicine and Parasitology, 2003, 97:215–220.
           42.  Baird JK et al. Chloroquine for the treatment of uncomplicated malaria in Guyana. Annals
                of Tropical Medicine and Parasitology, 2002, 96:339–348.
           43.  Castillo CM, Osorio LE, Palma GI. Assessment of therapeutic response of Plasmodium   A9
                vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in
                Columbia. Memórias do Instituto Oswaldo Cruz, 2002, 97:559–562.
           44.  Ruebush TK et al. Choloroquine-resistant Plasmodium vivax malaria in Peru. American
                Journal of Tropical Medicine and Hygiene, 2003, 69:548–552.
           45.  Baird JK et al. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium
                falciparum at Nabire, Irian Jaya, Indonesia. American Journal of Tropical Medicine and
                Hygiene, 1997, 56:627–631.
                                                                                      183
   192   193   194   195   196   197   198   199   200   201   202